Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to determine to what extent anticancer immune cells mobilized by aerobic exercise exhibit migratory and functional capacity towards cancer cells in patients undergoing treatment for breast or colorectal cancer. The main questions it aims to answer are: • Do anticancer immune cells mobilized by aerobic exercise will display migratory and functional capacity in patients undergoing treatment for curable breast or colorectal cancer? Hypothesis: exercise will promote cell migration and these cells will display anti-cancer functional characteristics, suggesting a possible adjuvant and immunotherapeutic use of exercise. • Do the magnitude of this anti-cancer immune response to exercise depend on the intensity of exercise? Hypothesis: the achievement of a higher intensity of effort will enable greater mobilization of the cytotoxic lymphocytes of interest, but also the expression of markers predicting a more interesting adjuvant potential to immunotherapy. Researchers will compare the effect of two exercise sessions, one moderate-intensity continuous exercise session (MOD) and one high-intensity interval exercise (HIIE) on the migration and anticancer potentials of mobilized immune cells. Individuals aged between 40 and 70 with curable colon or breast cancer will be recruited to carry out a cross-over study with two experimental conditions. After a preliminary assessment visit, they will take part in: * Two familiarization visits to validate the exercise prescription * Two experimental visits (HIIE and MOD). During these conditions, blood samples will be taken before, after and 1 hour after the end of exercise to collect immune cells in the blood. At the end of the visits, participants will leave with an accelerometer to wear for three days depending on conditions, and a notebook containing a questionnaire to assess fatigue levels over the same three days.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie raka piersi lub tłustej kiszki bez przerzutów
- •Wiek od 40 do 70 lat
- •Rozpoczęcie chemioterapii lub immunoterapii z co najmniej trzema zaplanowanymi zabiegami do końca cyklu
- •Dobry stan ogólny (ECOG 0-1)
- •Zdolność do wykonywania ćwiczeń aerobowych o średniej intensywności lub jazdy na rowerze bez bólu
✗ Disqualifies
- •Problemy ortopedyczne, sercowe lub metaboliczne uniemożliwiające bezpieczne ćwiczenia
- •Niekontrolowana choroba lub stan zdrowotny
- •Stosowanie leków beta-blocking
- •Planowana operacja podczas trwania badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 40 Years
- Maximum age
- 70 Years
- Last updated (source)
- August 29, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Research Center on Aging
Sherbrooke, Canada
Research Center on Aging
Sherbrooke, Canada
Trial contact
Eléonor Riesco, PhD
Laurence Poirier, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.